151 related articles for article (PubMed ID: 1536715)
1. Regional brain kinetics of 6-fluoro-(beta-11C)-L-dopa and (beta-11C)-L-dopa following COMT inhibition. A study in vivo using positron emission tomography.
Hartvig P; Lindner KJ; Tedroff J; Bjurling P; Hörnfelt K; Långström B
J Neural Transm Gen Sect; 1992; 87(1):15-22. PubMed ID: 1536715
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography in drug evaluation: influence of three different catechol-O-methyltransferase inhibitors on metabolism of [NCA] 6-[18F]fluoro-L-dopa in rhesus monkey.
Günther I; Psylla M; Reddy GN; Antonini A; Vontobel P; Reist HW; Zollinger A; Nickles RJ; Beer HF; Schubiger PA
Nucl Med Biol; 1995 Oct; 22(7):921-7. PubMed ID: 8547890
[TBL] [Abstract][Full Text] [Related]
3. A comparison of 11C-labeled L-DOPA and L-fluorodopa as positron emission tomography tracers for the presynaptic dopaminergic system.
Torstenson R; Tedroff J; Hartvig P; Fasth KJ; Långström B
J Cereb Blood Flow Metab; 1999 Oct; 19(10):1142-9. PubMed ID: 10532639
[TBL] [Abstract][Full Text] [Related]
4. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.
Napolitano A; Bellini G; Borroni E; Zürcher G; Bonuccelli U
Parkinsonism Relat Disord; 2003 Jan; 9(3):145-50. PubMed ID: 12573869
[TBL] [Abstract][Full Text] [Related]
5. Central action of benserazide after COMT inhibition demonstrated in vivo by PET.
Tedroff J; Hartvig P; Bjurling P; Andersson Y; Antoni G; Långström B
J Neural Transm Gen Sect; 1991; 85(1):11-7. PubMed ID: 1867835
[TBL] [Abstract][Full Text] [Related]
6. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease.
Ceravolo R; Piccini P; Bailey DL; Jorga KM; Bryson H; Brooks DJ
Synapse; 2002 Mar; 43(3):201-7. PubMed ID: 11793426
[TBL] [Abstract][Full Text] [Related]
7. Cerebral 6-[18F]fluoro-L-DOPA uptake in rhesus monkey: pharmacological influence of aromatic amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) inhibition.
Psylla M; Günther I; Antonini A; Vontobel P; Reist HW; Zollinger A; Leenders KL
Brain Res; 1997 Aug; 767(1):45-54. PubMed ID: 9365014
[TBL] [Abstract][Full Text] [Related]
8. Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-Dopa trapping in MPTP-induced parkinsonism in monkeys.
Doudet DJ; Chan GL; Holden JE; Morrison KS; Wyatt RJ; Ruth TJ
Neuropharmacology; 1997 Mar; 36(3):363-71. PubMed ID: 9175615
[TBL] [Abstract][Full Text] [Related]
9. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.
Männistö PT; Tuomainen P; Tuominen RK
Br J Pharmacol; 1992 Mar; 105(3):569-74. PubMed ID: 1628144
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of an 18F-labeled dopa prodrug as a PET tracer for studying brain dopamine metabolism.
Ishiwata K; Shinoda M; Ishii S; Nozaki T; Senda M
Nucl Med Biol; 1996 Apr; 23(3):295-301. PubMed ID: 8782240
[TBL] [Abstract][Full Text] [Related]
11. Graphical analysis of 6-fluoro-L-dopa trapping: effect of inhibition of catechol-O-methyltransferase.
Holden JE; Doudet D; Endres CJ; Chan GL; Morrison KS; Vingerhoets FJ; Snow BJ; Pate BD; Sossi V; Buckley KR; Ruth TJ
J Nucl Med; 1997 Oct; 38(10):1568-74. PubMed ID: 9379194
[TBL] [Abstract][Full Text] [Related]
12. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.
Kaakkola S; Gordin A; Männistö PT
Gen Pharmacol; 1994 Sep; 25(5):813-24. PubMed ID: 7835624
[TBL] [Abstract][Full Text] [Related]
13. The part played by catechol-O-methyltransferase in the plasma kinetics of 3,4-dihydroxyphenylglycol and 3,4-dihydroxyphenylalanine in the anaesthetized rabbit.
Friedgen B; Halbrügge T; Graefe KH
Naunyn Schmiedebergs Arch Pharmacol; 1993 Feb; 347(2):155-61. PubMed ID: 8474536
[TBL] [Abstract][Full Text] [Related]
14. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.
Cumming P; Gjedde A
Synapse; 1998 May; 29(1):37-61. PubMed ID: 9552174
[TBL] [Abstract][Full Text] [Related]
15. Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum.
Kaakkola S; Wurtman RJ
J Neurochem; 1993 Jan; 60(1):137-44. PubMed ID: 8417137
[TBL] [Abstract][Full Text] [Related]
16. Brain kinetics of L-[beta-11C]dopa in humans studied by positron emission tomography.
Hartvig P; Agren H; Reibring L; Tedroff J; Bjurling P; Kihlberg T; Långström B
J Neural Transm Gen Sect; 1991; 86(1):25-41. PubMed ID: 1751027
[TBL] [Abstract][Full Text] [Related]
17. Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues.
Zürcher G; Colzi A; Da Prada M
J Neural Transm Suppl; 1990; 32():375-80. PubMed ID: 2089102
[TBL] [Abstract][Full Text] [Related]
18. Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA.
Doudet DJ; Chan GL; Holden JE; Pate BD; Morrison KS; Calne DB; Ruth TJ
Eur J Pharmacol; 1997 Sep; 334(1):31-8. PubMed ID: 9346324
[TBL] [Abstract][Full Text] [Related]
19. Effect of catechol-O-methyl transferase inhibition on peripheral and central metabolism of 6-[18F]fluoro-L-dopa.
Pauwels T; Dethy S; Goldman S; Monclus M; Luxen A
Eur J Pharmacol; 1994 May; 257(1-2):53-8. PubMed ID: 8082707
[TBL] [Abstract][Full Text] [Related]
20. Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine: an in vivo study in rats.
Brannan T; Martínez-Tica J; Yahr MD
Neurology; 1992 Mar; 42(3 Pt 1):683-5. PubMed ID: 1549240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
